
Adult Psoriasis Biologic Pathway

Gloucestershire Hospitals



Note 2: Dose escalation

Hyrimoz[®] : Can increase to 40mg weekly

Remsima[®] IV: Consider drug level and anti-drug antibody testing to guide dose and frequency

Cosentyx[®] : If ≥ 90kg, can increase to 300mg every 2 weeks

Stelara[®] :

-If <100kg increase to 90mg every 12 weeks

-If \geq 100kg increase to 90mg every 8 weeks

Illumetri[®] : If ≥ 90kg or high disease burden can increase to 200mg dosing

Cimzia[®] : Can increase to 400mg every 2 weeks only in those patients who are planning a pregnancy, currently pregnant or lactating.

Note 1	Druge	Licensed	Patient and clinical considerations
Therapeutic	Drugs	for	Refer to dermatology local guidance for further details
class		psoriatic arthritis	Refer to dermatology local guidance for further details
Anti-TNF	Hyrimoz [®] SC (Adalimumab) Remsima [®] IV/SC (Infliximab) Cimzia [®] SC (Certolizumab pegol) Benepali [®] SC (Etanercept)	Yes (all)	Contraindications: Demyelinating disease, heart failure (etanercept cautioned for both) Hyrimoz [®] /Remsima [®] first line biologics in Inflammatory Bowel Disease Cimzia [®] is the drug of choice in pregnant or lactating patients or those who are planning a pregnancy Cimzia [®] is contraindicated in latex allergy
Anti IL-17	Bimzelx [®] SC (Bimekizumab) Taltz [®] SC (Ixekizumab) Kyntheum [®] SC (Brodalumab) Cosentyx [®] SC (Secukinumab)	Yes Yes No Yes	Avoid in Inflammatory Bowel Disease IL-17 as a class is considered to be relatively fast onset of action compared to other options Cosentyx [®] is contraindicated in latex allergy Kyntheum [®] is cautioned in patients with depression
Anti IL-23	Tremfya [®] SC (Guselkumab) Ilumetri [®] SC (Tildrakizumab) Skyrizi [®] SC (Risankizumab)	Yes No Yes	Continuous homecare nursing service available if adherence concerns or if patients are unable to self-inject
Anti IL-12/23	Stelara [®] SC (Ustekinumab)	Yes	Continuous homecare nursing service available if adherence concerns or if patients are unable to self-inject Also used in the management of Inflammatory Bowel Disease Stelara [®] is contraindicated in latex allergy
PDE4 inhibitor	Otezla [®] PO (Apremilast)	Yes	Oral therapy and requires less monitoring than other options Cautioned in patients with depression
TYK2 inhibtor Authors: Dr Er Approved by: Review date:	Sotyktu® PO (Deucravacitinib) nily Davies and Leela Terry Drugs and Therapeutics Committee A October 2024	No ugust 2019, this	Oral therapy which requires no monitoring Not as effective as other biological options but more effective than apremilast. ucate offection of the state of the st